17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Eukaryotic translation initiation factor 4E binding protein 1 (eIF4EBP1)

Endocrine/metabolic disease INDICATION: Obesity Mouse studies suggest promoting eIF4EBP1 expression could help treat obesity. In mice fed a high-fat diet, transgenic expression of human eIF4EBP1 decreased body weight, serum levels of leptin, triglycerides and IL-6,...
07:00 , Mar 24, 2016 |  BC Innovations  |  Strategy

Combo platter

In the last few years, Incyte Corp. has changed its strategy to incorporate combination options into the design and selection of its NCEs from the start. The company has developed an approach to target independent...
07:00 , Sep 11, 2014 |  BC Innovations  |  Cover Story

Kinase convergence on eIF4F

Researchers in France have shown that resistance to BRAF and MEK inhibitors in melanoma and possibly other cancers can be driven by pathways that converge on the eukaryotic translation initiation factor 4F complex. 1 The...
07:00 , Aug 2, 2012 |  BC Innovations  |  Cover Story

Cylene takes pol position in cancer

Australian and U.S. researchers have shown that a small molecule inhibitor of RNA polymerase I blocked tumor growth in mouse models of lymphoma. 1 Cylene Pharmaceuticals Inc. and the Peter MacCallum Cancer Centre plan to...